These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11468119)

  • 1. Prolonged visual illusions induced by mefloquine (Lariam): a case report.
    Borruat FX; Nater B; Robyn L; Genton B
    J Travel Med; 2001; 8(3):148-9. PubMed ID: 11468119
    [No Abstract]   [Full Text] [Related]  

  • 2. Case study: neuropsychiatric symptoms associated with the antimalarial agent mefloquine.
    Clattenburg RN; Donnelly CL
    J Am Acad Child Adolesc Psychiatry; 1997 Nov; 36(11):1606-8. PubMed ID: 9394947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maculopathy associated with mefloquine (Lariam) therapy for malaria prophylaxis.
    Walker RA; Colleaux KM
    Can J Ophthalmol; 2007 Feb; 42(1):125-6. PubMed ID: 17361254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Psychopathological phenomena in long-term follow-up of acute psychosis after preventive mefloquinine (Lariam) administration].
    Meszaros K; Kasper S
    Nervenarzt; 1996 May; 67(5):404-6. PubMed ID: 9005352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eye disorders reported with the use of mefloquine (Lariam(®)) chemoprophylaxis--A drug safety database analysis.
    Adamcova M; Schaerer MT; Bercaru I; Cockburn I; Rhein HG; Schlagenhauf P
    Travel Med Infect Dis; 2015; 13(5):400-8. PubMed ID: 26119539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malaria, mefloquine and the mind.
    Ingram RJ; Ellis-Pegler RB
    N Z Med J; 1997 Apr; 110(1042):137-8. PubMed ID: 9152353
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mood disorder after malaria prophylaxis with mefloquine (two case reports)].
    Oueriagli Nabih F; Touhami M; Laffinti A; Abilkacem L
    Encephale; 2011 Oct; 37(5):393-6. PubMed ID: 22032283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mefloquine prophylaxis--revisited.
    Cohen J
    Aust Fam Physician; 1997 Aug; 26(8):909. PubMed ID: 9267055
    [No Abstract]   [Full Text] [Related]  

  • 9. Health advice for travelers.
    Abell L
    N Engl J Med; 2000 Oct; 343(14):1045-6. PubMed ID: 11023399
    [No Abstract]   [Full Text] [Related]  

  • 10. Mefloquine for preventing malaria in nonimmune adult travelers.
    Cayley WE
    Am Fam Physician; 2004 Feb; 69(3):521-2. PubMed ID: 14971832
    [No Abstract]   [Full Text] [Related]  

  • 11. Case report: Peripheral polyneuropathy and mefloquine prophylaxis.
    Chester AC; Sandroni P
    Am J Trop Med Hyg; 2011 Dec; 85(6):1008-9. PubMed ID: 22144435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological concerns regarding the relation between mefloquine and serious psychiatric events in females.
    Tepper ML; Strauss BA
    J Clin Psychiatry; 2006 Jan; 67(1):164; author reply 164-5. PubMed ID: 16426106
    [No Abstract]   [Full Text] [Related]  

  • 13. Mefloquine-induced pneumonitis.
    Soentjens P; Delanote M; Van Gompel A
    J Travel Med; 2006; 13(3):172-4. PubMed ID: 16706949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malaria prophylaxis and the media.
    Clift S; Grabowski P
    Lancet; 1996 Aug; 348(9023):344. PubMed ID: 8709720
    [No Abstract]   [Full Text] [Related]  

  • 15. Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands.
    van Riemsdijk MM; Sturkenboom MC; Pepplinkhuizen L; Stricker BH
    J Clin Psychiatry; 2005 Feb; 66(2):199-204. PubMed ID: 15705005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between body weight and tolerance to mefloquine prophylaxis in non-immune adults: results of a questionnaire-based study.
    Ollivier L; Tifratene K; Josse R; Keundjian A; Boutin JP
    Ann Trop Med Parasitol; 2004 Sep; 98(6):639-41. PubMed ID: 15324471
    [No Abstract]   [Full Text] [Related]  

  • 17. [Mefloquine and ototoxicity: a report of 3 cases].
    Fusetti M; Eibenstein A; Corridore V; Hueck S; Chiti-Batelli S
    Clin Ter; 1999; 150(5):379-82. PubMed ID: 10687269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Serious" and "severe" adverse drug reactions need defining.
    Frankenfeld C
    BMJ; 2004 Sep; 329(7465):573. PubMed ID: 15345644
    [No Abstract]   [Full Text] [Related]  

  • 19. [Neuropsychiatric side effects of malarial prophylaxis with mefloquine (Lariam)].
    Minei-Rachmilewitz T
    Harefuah; 1999 Jul; 137(1-2):25-7, 87. PubMed ID: 10959270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropsychiatric events and travel: do antimalarials play a role?
    Schlagenhauf P; Steffen R
    J Travel Med; 2000; 7(5):225-6. PubMed ID: 11231204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.